The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
Sarah V. Holt(AstraZeneca (United Kingdom)), Paul D. Smith(Abzena (United Kingdom))
Cited by 111
Related Papers
Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells
|Cancer Research Communications|2022|8